ClinicalTrials.gg
CompletedNCT00417079TROPICUpdated Mar 10, 2011Results posted

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

A Phase 3 interventional study of cabazitaxel (XRP6258) (RPR116258) and mitoxantrone in Neoplasms and Prostatic Neoplasms, sponsored by Sanofi. Completed at 26 sites in 26 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-10.

Primary conditionProstatic NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's listed conditions name Prostatic Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
4th of 46
755 · median 60
Started
2007
the only one that year
Phase 3
7 of 46
none open now
Registered
1st of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 3, and was the 1st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere®-containing regimen. The primary objective is overall survival. Secondary objectives include progression free survival, overall response rate, prostate-specific antigen (PSA) response/progression, pain response/progression, overall safety, and pharmacokinetics. Patients will be treated until disease progression, death, unacceptable toxicity, or for a maximum of 10 cycles. Patients will have long-term follow-up for a maximum of up to 2 years.

03

Conditions studied

  • Neoplasms
  • Prostatic Neoplasms

Browse trials for

Keywords

  • Cancer
  • Prostate
04

In context

Prostatic Neoplasms Reclassified

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

This study's enrollment of 755 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed adenocarcinoma of the prostate that is to hormone therapy and previously treated with a Taxotere®-containing regimen.
  2. Documented progression of disease (demonstrating at least one visceral or soft tissue lesion, including a new lesion). Patients with non- must have documented rising prostate-specific antigen (PSA) levels or appearance of new lesion.
  3. Surgical or hormone-induced castration
  4. > 2 months
  5. (ECOG) performance status 0 - 2

Exclusion criteria

Exclusion criteria

  1. Previous treatment with mitoxantrone
  2. Previous treatment with \<225 mg/m\^2 cumulative dose of Taxotere (or docetaxel)
  3. Prior radiotherapy to ≥ 40% of bone marrow
  4. Surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks prior to enrollment in the study
  5. Other prior , except for adequately treated superficial basal cell skin cancer, or any other cancer from which the patient has been disease-free for less than 5 years
  6. Known brain or
  7. Other concurrent serious illness or medical conditions
  8. Inadequate organ function evidenced by unacceptable laboratory results

The investigator will evaluate whether there are other reasons why a patient may not participate.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
755 participants (actual)

Study arms

  • Active comparator
    Mitoxantrone + Prednisone

    Mitoxantrone + Prednisone

    Drug: mitoxantrone · Drug: prednisone

  • Experimental
    Cabazitaxel + Prednisone

    Cabazitaxel + Prednisone

    Drug: cabazitaxel (XRP6258) (RPR116258) · Drug: prednisone

Interventions

  • 25 mg/m\^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle

    Also known as: Jevtana

  • 12 mg/m\^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle

  • 10 mg daily administered by oral route

07

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first.

    Time frame: From the date of randomization up to 104 weeks (study cut-off)

Secondary outcomes

  1. Time to Progression Free Survival (PFS)

    Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first

    Time frame: From the date of randomization up to 104 weeks (study cut-off)

  2. Overall Tumor Response

    Tumor Overall Response Rate (ORR) (only in patients with measurable disease): Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria. Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD. Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response.

    Time frame: From the date of randomization up to 104 weeks (study cut-off)

  3. Time to Tumor Progression

    Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST)

    Time frame: From the date of randomization up to 104 weeks (study cut-off)

  4. Time to Prostatic Specific Antigen (PSA) Progression

    In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later. In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later.

    Time frame: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)

  5. PSA (Prostate-Specific Antigen) Response

    PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later.

    Time frame: from baseline up to 104 weeks (study cut-off)

  6. Time to Pain Progression

    Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score \& noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy. Evaluation of the PPI \& analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)

    Time frame: from baseline up to 104 weeks (study cut-off)

  7. Pain Response

    Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks.

    Time frame: from baseline up to 104 weeks (study cut-off)

08

Results

Posted Dec 23, 2010

Participant flow

Multicenter study: 146 actives sites from 26 countries in Europe, USA, South America and Asia Pacific region. Study initiation date: January 2nd, 2007; study completion date/study cut off date: September 25th, 2009.

Participant flow — Overall Study
MilestoneMitoxantrone + PrednisoneCabazitaxel + Prednisone
Started377378
Completed46105
Not completed331273
Withdrew: Disease progression267180
Withdrew: Adverse event3267
Withdrew: Non-compliance to protocol01
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject178
Withdrew: Not treated67
Withdrew: Screened failure21
Withdrew: Investigator's decision14
Withdrew: Non-confirmed disease progression11
Withdrew: Clinical deterioration10
Withdrew: Screening error21
Withdrew: Withdrawal by subject's family01
Withdrew: Patient unable to come to the clinic01
Withdrew: Abnormal liver function tests01

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first.

Time frame:
From the date of randomization up to 104 weeks (study cut-off)
Reported as:
Median · Months
Overall Survival
MonthsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Overall Survival12.7 (11.6 to 13.7)15.1 (14.1 to 16.3)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Log Rank · p = <0.0001 (A 2-sided significance level of 0.0452 was used for the final analysis based on an interim analysis performed after 307 events with an adjusted significance level of 0.016 based on the O'Brien-Fleming type 1 error spending function.)Analysis was performed by using a log-rank comparisons stratified according to disease measurability and ECOG performance status (0-1 versus 2)
SecondaryTime to Progression Free Survival (PFS)

Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first

Time frame:
From the date of randomization up to 104 weeks (study cut-off)
Reported as:
Median · Months
Time to Progression Free Survival (PFS)
MonthsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Time to Progression Free Survival (PFS)1.4 (1.4 to 1.7)2.8 (2.4 to 3.0)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Log Rank · p = <0.0001
SecondaryOverall Tumor Response

Tumor Overall Response Rate (ORR) (only in patients with measurable disease): Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria. Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD. Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response.

Time frame:
From the date of randomization up to 104 weeks (study cut-off)
Reported as:
Number · percentage of participants
Overall Tumor Response
percentage of participantsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Overall Tumor Response4.4 (1.6 to 7.2)14.4 (9.6 to 19.3)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Chi-squared · p = 0.0005
SecondaryTime to Tumor Progression

Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST)

Time frame:
From the date of randomization up to 104 weeks (study cut-off)
Reported as:
Median · Months
Time to Tumor Progression
MonthsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Time to Tumor Progression5.4 (4.7 to 6.5)8.8 (7.4 to 9.6)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Log Rank · p = <0.0001 · Cox proportional hazard: 0.61 · 95% CI 0.49 to 0.76Hazard ratio (HR) \< 1 favours the cabazitaxel group and \> 1 favours the mitoxantrone group.
SecondaryTime to Prostatic Specific Antigen (PSA) Progression

In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later. In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later.

Time frame:
at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
Reported as:
Median · Months
Time to Prostatic Specific Antigen (PSA) Progression
MonthsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Time to Prostatic Specific Antigen (PSA) Progression3.1 (2.2 to 4.4)6.4 (5.1 to 7.3)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Log Rank · p = 0.0010 · Cox proportional hazard: 0.75 · 95% CI 0.63 to 0.90Hazard ratio (HR) \< 1 favours the cabazitaxel group and \> 1 favours the mitoxantrone group.
SecondaryPSA (Prostate-Specific Antigen) Response

PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later.

Time frame:
from baseline up to 104 weeks (study cut-off)
Reported as:
Number · Percentage of participants
PSA (Prostate-Specific Antigen) Response
Percentage of participantsMitoxantrone + PrednisoneCabazitaxel + Prednisone
PSA (Prostate-Specific Antigen) Response17.8 (13.7 to 22.0)39.2 (33.9 to 44.5)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Chi-squared · p = 0.0002
SecondaryTime to Pain Progression

Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score \& noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy. Evaluation of the PPI \& analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)

Time frame:
from baseline up to 104 weeks (study cut-off)
Reported as:
Median · Months
Time to Pain Progression
MonthsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Time to Pain ProgressionNA (NA to NA)11.1 (8.1 to NA)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Log Rank · p = 0.5192 · Cox proportional hazard: 0.91 · 95% CI 0.69 to 1.19Hazard ratio (HR) \< 1 favours the cabazitaxel group and \> 1 favours the mitoxantrone group.
SecondaryPain Response

Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks.

Time frame:
from baseline up to 104 weeks (study cut-off)
Reported as:
Number · Percentage of participants
Pain Response
Percentage of participantsMitoxantrone + PrednisoneCabazitaxel + Prednisone
Pain Response7.7 (3.7 to 11.8)9.2 (4.9 to 13.5)
Statistical analysis
  • Mitoxantrone + Prednisone vs Cabazitaxel + Prednisone · Chi-squared · p = 0.6286

Adverse events

Collected over Adverse events are collected from the time to the first patient signed an informed consent form until 30 days after the administration of the last cycle of the study treatment to the last patient (i.e. 104 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mitoxantrone + Prednisone—77/371 (20.8%)323/371 (87.1%)
Cabazitaxel + Prednisone—145/371 (39.1%)350/371 (94.3%)
Most frequent serious events
Showing 10 of 146
Most frequent serious events
EventMitoxantrone + PrednisoneCabazitaxel + Prednisone
Febrile neutropeniaBlood and lymphatic system disorders4/37125/371
NeutropeniaBlood and lymphatic system disorders3/37118/371
Disease progressionGeneral disorders11/3711/371
HaematuriaRenal and urinary disorders3/37110/371
DiarrhoeaGastrointestinal disorders0/3719/371
VomitingGastrointestinal disorders2/3716/371
Abdominal painGastrointestinal disorders0/3716/371
PyrexiaGeneral disorders1/3716/371
PneumoniaInfections and infestations2/3716/371
Renal failureRenal and urinary disorders0/3716/371
Most frequent other events
Showing 10 of 35
Most frequent other events
EventMitoxantrone + PrednisoneCabazitaxel + Prednisone
DiarrhoeaGastrointestinal disorders39/371170/371
FatigueGeneral disorders102/371136/371
NauseaGastrointestinal disorders84/371127/371
VomitingGastrointestinal disorders36/37180/371
AstheniaGeneral disorders46/37176/371
ConstipationGastrointestinal disorders56/37173/371
NeutropeniaBlood and lymphatic system disorders38/37166/371
AnorexiaMetabolism and nutrition disorders39/37159/371
Back painMusculoskeletal and connective tissue disorders41/37158/371
HaematuriaRenal and urinary disorders13/37158/371

Baseline characteristics

Age Continuous
Age Continuous(years)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
Median67.0 (47 to 89)68.0 (46 to 92)67 (46 to 92)
Sex/Gender, Customized
Sex/Gender, Customized(participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
Male377378755
Region of Enrollment
Region of Enrollment(participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
United States10697203
Taiwan4711
Slovakia112
Spain10919
Chile91221
Russian Federation6410
Italy171835
India11920
France444690
Denmark192645
South Africa7916
Netherlands8917
Korea, Republic of8715
Finland415
Turkey171936
United Kingdom172037
Hungary8715
Czech Republic101222
Mexico235
Canada161632
Argentina7310
Brazil7411
Belgium161531
Singapore639
Germany61117
Sweden111021
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
0 - Fully Active120141261
1 - Ambulatory, Restricted Activity224209433
2 - Ambulatory, No Work Activities332861
Prostatic Specific Antigen PSA
Prostatic Specific Antigen PSA(ng/mL)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
Median127.5 (2 to 11220)143.9 (2 to 7842)135.00 (2 to 11220)
Measurable disease
Measurable disease(Participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
Measurable disease204201405
Not Measurable disease173177350
Extent of disease
Extent of disease(Participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
Metastatic356364720
Locoregional Recurrence201434
Missing101
Tumor Location: number of sites involved
Tumor Location: number of sites involved(Participants)Mitoxantrone + PrednisoneCabazitaxel + PrednisoneTotal
1134146280
2117112229
37873151
4 or more434487
Missing538
09

Study locations

26 sites
  • sanofi-aventis US
    Bridgewater, New Jersey 08807, United States
  • sanofi-aventis Argentina
    Buenos Aires, Argentina
  • sanofi-aventis Belgium
    Diegem, Belgium
  • sanofi-aventis Brazil
    Sao Paulo, Brazil
  • sanofi-aventis Canada
    Laval, Quebec, Canada
  • sanofi-aventis Chile
    Santiago, Chile
  • sanofi-aventis Czech Republic
    Praha, Czech Republic
  • sanofi-aventis Denmark
    Horsholm, Denmark
  • sanofi-aventis Finland
    Helsinki, Finland
  • sanofi-aventis France
    Paris, France
  • sanofi-aventis Germany
    Berlin, Germany
  • Sanofi-Aventis Hungaria
    Budapest, Hungary
  • sanofi-aventis India
    Mumbai, India
  • sanofi-aventis Italy
    Milano, Italy
  • sanofi-aventis South Korea
    Seoul, Korea, Republic of
  • sanofi-aventis Mexico
    Mexico, Mexico
  • sanofi-aventis Netherlands
    Gouda, Netherlands
  • sanofi-aventis Russia
    Moscow, Russian Federation
  • sanofi-aventis Singapore
    Singapore, Singapore
  • sanofi-aventis Slovakia
    Bratislava, Slovakia
  • sanofi-aventis South Africa
    Midrand, South Africa
  • sanofi-aventis Spain
    Barcelona, Spain
  • sanofi-aventis Sweden
    Bromma, Sweden
  • sanofi-aventis Taiwan
    Taipei, Taiwan
  • sanofi-aventis Turkey
    Istanbul, Turkey
  • sanofi-aventis UK
    Guildford, Surrey, United Kingdom
10

References and documents

Publications

  • Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015 Apr;26(4):750-755. doi: 10.1093/annonc/mdu587. Epub 2014 Dec 23. PubMed 25538172 ↗
  • Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, Gravis G, Devin J, Shen L, de Bono JS, Sartor AO; TROPIC Investigators. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013 Sep;24(9):2402-8. doi: 10.1093/annonc/mdt194. Epub 2013 May 30. PubMed 23723295 ↗
  • Pouessel D, Oudard S, Gravis G, Priou F, Shen L, Culine S. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France]. Bull Cancer. 2012 Jul-Aug;99(7-8):731-41. doi: 10.1684/bdc.2012.1608. French. PubMed 22743148 ↗
  • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. PubMed 20888992 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2006
First posted
Dec 29, 2006
Start
Jan 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Dec 23, 2010
Last update
Mar 10, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00417079
Lead sponsor
Sanofi
First posted
Dec 29, 2006
Start date
Jan 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Dec 23, 2010
Last update
Mar 10, 2011

Study contacts

ICD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion